Podcasts about Pancreatic cancer

Happy Halloween! On October 31, do you give out candy? Do you turn your lights off and pretend not to be home? Do you go to Halloween parties? What "vampires" are out there sucking your wallet dry? On this week's episode, Shawn & George take a funny look at those "vampires" that you should avoid, like Subscription Vampires Convenience Fee Vampires Tipping Vampires Lifestyle Vampires Tax Debt Vampires Buy Now, Pay Later Vampires Friend / Family Vampires Overdraft Vampires Store Credit / BOGO Vampires Interest Vampires And more ... You can also listen to other Halloween-themed shows like Episode 438: Debt Graveyard Episode 211: Zombie Cars Episode 88: Zombie Debt Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026

Dr Norman Swan of the ABC's Health Report and the podcast, What's That Rash, joined Philip Clark and listeners to Nightlife.

How are you handling the rising cost of health care for your parents? How can you talk to your mother & father about the rising costs of health care and senior living? Should your parents age at home or in an assisted living facility? This week, Shawn & George talk to Rachel Aguanno, owner of Home Care Assistance Tampa Bay.  Rachel's company assists seniors to live at home. Rachel was a HUGE help to Shawn when his wife was in hospice at home at the end of 2023. Specifically, we talk about: Care-giving as a side job; What a home care assistance company can or cannot do; Any tax breaks, insurance, government programs, or veteran benefits available to help pay for home health care; Hospice v. Home Health Care v Assisted Living; Expenses people don't think about; and other budget considerations. Rachel can be reached at RAguanno@HomeCareAssistance.com or her website www.HomeCareAssistanceTampaBay.com.  Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026 

In this eye-opening episode of the Project Purple Podcast, host Dino Verrelli has a compelling conversation with Amy Johnston of Pennsylvania, a 34-year-old mother of three young kids, who says that listening to her instincts and advocating for herself made all the difference in her journey with pancreatic cancer. Amy talks about how just a couple of months ago, she was at her healthiest—working out five days a week, eating better, and feeling strong after having her third child. Then, in January, she says she was suddenly hit with severe GI pain during dinner, and immediately knew something was not right. She describes how she was continually told by her doctors that it was nothing serious, even after asking several times if the problem was related to her pancreas. Frustrated, Amy shares that she switched doctors and hospitals, which eventually led to the discovery of a 1.7 cm tumor. After a biopsy confirmed pancreatic cancer, she recounts the shock of learning the tumor had actually been visible months earlier, but was missed due to poor imaging and assumptions based on her youth. Choosing to have surgery at the University of Pennsylvania, Amy shares how she underwent a distal pancreatectomy and splenectomy in May. In early June, she began her 12 rounds of chemotherapy and shares candidly about the challenges of treatment and the importance of staying active and positive despite the fatigue and side effects. She also talks about the comfort she's found in community support, creative outlets like crocheting, and especially in her growing faith, sharing that she plans to be baptized in a few months. Her story is a powerful reminder of the importance of advocating for yourself and pushing for answers. Amy stresses, “If I hadn't switched doctors, I could have thought this was a stomach bug.” She encourages others to focus on the facts of their own situation, connect with others facing similar journeys, and maintain hope throughout. Tune in for an honest and inspiring episode about resilience, motherhood, and faith in the face of pancreatic cancer. Subscribe to the Project Purple Podcast for more powerful stories from the pancreatic cancer community. If you'd like to donate to or support Project Purple's mission of a world without pancreatic cancer, please visit https://www.projectpurple.org/ and follow us on social media with these links: https://www.facebook.com/Run4ProjectPurple https://www.instagram.com/projectpurple/ https://twitter.com/Run4Purple

Dr Akila Viswanathan talks with Dr Amol Narang about the latest edition of Seminars in Radiation Oncology focused on the multidisciplinary treatment of pancreatic cancer.

When does an entrepreneur make time? How can an entrepreneur work 27 hours a day? How hard (or easy) is work-life balance? On this week's episode, Shawn & George interview Tiffanie Kellog who today (if you're listening on the day of release) releases her FOURTH self-published book, The Entrepreneur's Guide to More Free Time.  Tiffanie is the Sock-it-to-'em Success Strategist!  Since 2005, Tiffanie has been revolutionizing entrepreneurs' paths, unlocking greater wealth, freedom, and joy! As the creator of “eTiffanies” — epiphanies inspired by Tiffanie — she is known for her signature socks (over 400 pairs!), a charming southern accent, and her unique ability to inspire and empower others. Whether delivering dynamic keynote presentations, training locally and globally (often virtually), writing her next book, or leading her More Abundant Entrepreneurs community, Tiffanie loves helping people create the life they desire. With a passion for blending fun and strategy, Tiffanie helps her clients focus on achieving their goals while loving the journey. Her secret to success? Loving what she does so much that no one can tell if she's working or playing! Are you ready to sock it to your challenges, make more money, save time, and have fun? This is Tiffanie's seventh appearance on the podcast: Episode 381 (Talking about the no spend challenge) Episode 332 (Making time to crush your debt) Episode 242 (More money through masterminds) Episode 146 (13 months a year) Episode 76 (Referrals for Life) Episode 48 (Knock your socks off Speaking) Now Tiffanie is working on time management, or priority management, and how you can avoid BSO (Bright Shiney Objects) in your day.  And rather than Work/Life balance, we focus on Harmony or being "Off Balance On Purpose." You can get your copy of Tiffanie's new book or her previous three books at www.TiffanieKellog.com. And, Tiffanie is giving all of our listeners a free gift by going to this link: https://moreabundantentrepreneurs.com/moretime  Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026   

It's a wet, wet, wet Tuesday night for Mark Thompson and it's snowing in the Sierra Mountains. He had a weird celebrity encounter earlier today at the pharmacy with none other than Ashton Kutcher. R&B singer D'Angelo has died of pancreatic cancer at the age of 51.

R&B and neo-soul icon D’Angelo, born Michael D’Angelo Archer, has died at the age of 51 following a prolonged and courageous battle with pancreatic cancer. His family confirmed his passing on Tuesday, October 14, 2025, describing him as the "shining star of our family" who has been called home. The cause of death has been confirmed as pancreatic cancer, a fact that was not publicly disclosed prior to his death. D’Angelo, a Grammy-winning artist, was a leading figure in the neo-soul movement of the 1990s, known for his innovative fusion of classic R&B, gospel, funk, and hip-hop influences. His debut album, Brown Sugar (1995), and his critically acclaimed follow-up, Voodoo (2000), solidified his legacy, featuring hits like "Brown Sugar," "Lady," and "Untitled (How Does It Feel)". The family expressed their heartbreak over his passing but expressed gratitude for the "legacy of extraordinarily moving music" he leaves behind and requested privacy during their time of mourning. Spend weekday afternoons with Zweli. He keeps you in the loop with everything from music and movies to sport and pop culture. Hear what the Word on the Street is, test your skills with the high-pressure 6 Out of 6, and get ready to be entertained. Thank you for listening to an Afternoons with Zweli podcast Listen live on Primedia+ weekdays from 12:00 to 15:00 (SA Time) toAfternoons with Zweli broadcast on 947 https://www.primediaplus.com/station/947 For more from the show go to https://buff.ly/FeeL6wYor find all the catch-up podcasts here https://buff.ly/pRBikjo Subscribe to the 947 Weekly Newsletter herehttps://buff.ly/hf9IuR9 Follow us on social media 947 on Facebook: https://www.facebook.com/947Joburg/ 947 on TikTok: https://www.tiktok.com/@947joburg 947 on Instagram: https://www.instagram.com/947joburg 947 on X https://x.com/947 947 on YouTube: https://www.youtube.com/@947JoburgSee omnystudio.com/listener for privacy information.

TWiM explains studies that show that the oral bacterial and fungal microbiome are risk factors for pancreatic cancer, and the gut microbiome and pyruvate metabolism of older adults are a link between sleep quality and frailty. Hosts: Vincent Racaniello, Michael Schmidt, and Michele Swanson. Subscribe to TWiM (free) on Apple Podcasts, Spotify, Android, RSS, or by email. Become a patron of TWiM. Music used on TWiM is composed and performed by Ronald Jenkees and used with permission. Links for this episode Oral microbiome and pancreatic cancer risk (JAMA Oncol) 2025 Cancer Facts & Figures (ACS) Periodontal Disease: The Good, The Bad, and The Unknown (Front Cell Infect Micro) Socransky's disease complexes (Microorg) Microbiome, pyruvate metabolism, sleep quality, and frailty (Cell Rep) Pittsburgh Sleep Quality Index (pdf) How to score the sleep quality index (pdf) Take the TWiM Listener survey! Send your microbiology questions and comments (email or recorded audio) to twim@microbe.tv

JCO PO author Dr. Bryson Katona at the University of Pennsylvania Perelman School of Medicine shares insights into his article, “Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium” Host Dr. Rafeh Naqash and Dr. Katona discuss how, given differing guidelines as well as lack of detail about how PC surveillance should be performed, approaches to PC surveillance across centers often differs. TRANSCRIPT Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, I am thrilled to be joined by Dr. Bryson Katona, Director of the Gastrointestinal Cancer Genetics Program and Director of the Lynch Syndrome Program at the Penn Medicine's Abramson Cancer Center, and also lead author of the JCO PO article entitled "Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection or PRECEDE Consortium." Bryson, thanks for joining us again. Dr. Bryson Katona: Well, thank you so much for having me. I appreciate the opportunity. Dr. Rafeh Naqash: It is exciting to see that this work will be presented concurrently with the upcoming CGA meeting. Dr. Bryson Katona: Yes, it has been a fantastic partnership between JCO PO and the CGA-IGC and their annual meeting. And for those who may not be familiar, the CGA-IGC is the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. It is basically a professional organization dedicated to individuals who have hereditary GI cancer risk and focusing on providing education, promoting research, and really bringing together providers in this space from not just throughout the US but from across the globe as well. Dr. Rafeh Naqash: That is exciting to hear the kind of work you guys are doing. These are definitely interesting, exciting things. Now, going to what you have published, it is an area that is very evolving in the space of cancer screening, cancer surveillance, especially for a very aggressive cancer such as pancreatic cancer. Could you tell us currently, what are the general consensus? I know there are a lot of differences between different guidelines or societies, but what are the some of the commonalities if we were to start there first for pancreas cancer screening? If you are not a GI oncologist, you may not be aware that there is something with regards to pancreas cancer screening. Could you give us an overview and a background on that? Dr. Bryson Katona: Yeah, I think that pancreatic cancer screening really is one of the most controversial areas of all cancer screening. Part of that controversy is just because all the guidelines, the many different guidelines that are out there, do not always match up with one another, which I think leads to a lot of confusion, not just for providers but for patients who are trying to go through this, and then also the insurance companies in trying to get these screening tests covered. You know, when we think about who is eligible for pancreatic cancer screening, you know, it is important that these are not average-risk individuals. So really, we are only offering screening to high-risk individuals. And those can include people that have a strong family history of pancreatic cancer without a germline genetic susceptibility that has been identified. And those individuals we refer to as having familial pancreatic cancer. And the other big cohort is those individuals that carry hereditary pancreatic cancer predisposition. These are due to cancer risk mutations in many different genes, including many of the breast cancer risk genes like BRCA1 and BRCA2, as well as ATM and PALB2, but then other genes such as the Lynch syndrome genes, and then some of the higher risk genes such as those leading to Peutz-Jeghers syndrome as well as FAM, which is due to CDKN2A mutations. Dr. Rafeh Naqash: Thank you for that. Again, another practical question, and this may or may not be exactly related to your specific topic here, but perhaps to some extent there might be an overlap. If I get a patient from a colleague, and I see people in the early-phase clinical trial setting, so many different tumors for novel drugs, and I find an individual with, let us say, lung cancer who has a pathogenic BRCA2, which is somatic, should I be worried about pancreas cancer screening in that individual? Or have we not met that threshold yet in that circumstance? Dr. Bryson Katona: A lot of times these variants or these genes that are associated with pancreatic cancer risk get picked up on the somatic tumor profiles. Now, you know, whether or not those are truly germline variants typically requires the next step of referring the patient for germline genetic testing. So you know, I would not screen or make any kind of screening choices based on a somatic variant alone, but nowadays germline testing is so easy, so efficient, and relatively cheap that it is easy enough to confirm whether or not these somatic hits are in fact just somatic or may confer some germline risk in addition. Dr. Rafeh Naqash: So from what I understand from what you have said, there is debate about it, but it is something that should be done or is important enough that you need to figure out a path moving forward. Was that one of the reasons why you performed this project through this very interesting consortium called the PRECEDE Consortium? Dr. Bryson Katona: Yeah, that was one of our main reasons for doing this. And for those who do not know about the PRECEDE Consortium, this is a very large international, multi-institutional organization really focused on reducing death and improving survival from pancreatic cancer, primarily through increased and more effective use of screening and early detection strategies. This is an international consortium. There are over 50 sites now with nearly 10,000 patients who are enrolled in the consortium. So it really is at this point the largest prospective study of individuals who are at high risk for pancreatic cancer who are undergoing screening. And you know, I think amongst all of us in the consortium, just amongst discussions between colleagues and then, you know, often times when I see patients that are transferring their care to Penn who maybe had their screening done in another center before, what we were realizing is that, you know, although we all do a lot of screening, it seems that people are doing it slightly differently. And it does not seem that there is a real consensus approach across all centers about how pancreatic cancer screening should really be done. And it is one thing if you are thinking comparing, okay, well, maybe in the US we do it differently than, you know, in Europe or in other locations, but even among centers within the United States, we were still seeing very large differences in how pancreatic cancer screening in high-risk individuals were done. And so that led us to really pursue this survey of pancreatic cancer screening practices across the PRECEDE Consortium. So for this survey, we actually have 57 centers who the survey was sent out to. As you know, surveys are oftentimes very difficult to get good response rates back on, but we were fortunate to have 54 of the 57, or 95% of the centers, actually get back to us about their screening practices for this particular project. Dr. Rafeh Naqash: That is good to know. I hope you did not have to use any kind of gift cards for people to respond to the survey. But nevertheless, you got the information that you needed. Could you tell us what are some of the common denominators that you did identify and some of the differences that you identified? From your perspective, it sounds like there is no established consensus guidelines. There are different societies that have different perspectives on it. So I am sure some of what you found will probably have implications in maybe creating some guidelines. Is that a fair statement? Dr. Bryson Katona: Definitely a fair statement, and we found some very interesting results. I think one important result is really just the heterogeneity in the consortium. And so even before we got into pancreatic cancer screening practices, we also, we were asking consortium sites, “At your particular site, who is the individual that is leading these in-depth discussions about pancreatic cancer screening?” And while about 50% of the sites had a gastroenterologist leading it, about a quarter of the sites had a medical oncologist, a quarter had a surgeon leading these discussions as well. And we also found heterogeneity in who is the physician or the provider actually ordering these screening tests, again, with multiple different specialties across the different sites. But really one of the main areas that we wanted to hone in and focus on was how the different pancreatic cancer screening guidelines were actually utilized in each of the particular centers. The biggest controversial area in the field is for the gene mutation carriers, whether or not we should be requiring that a family history of pancreatic cancer be present in order for those individuals to qualify for pancreatic cancer screening. And the reason that is so controversial, let us take an example of BRCA1 and BRCA2 carriers. Currently, if you look through the guidelines, NCCN and the ASGE guidelines recommend that really all BRCA2 carriers undergo pancreatic cancer screening regardless of whether or not there is a family history, starting at age 50. However, other guidelines such as the AGA guidelines, or the AGA Clinical Practice Statement, as well as guidelines from the CAPS consortium, do recommend that a family history of pancreatic cancer be present in order to qualify for screening. But then we have different things for other genes. So for BRCA1 carriers, in fact, it is the ASGE guidelines that recommend all BRCA1 and 2 carriers undergo screening, whereas NCCN and the other guidelines that are out there do not recommend those individuals undergo screening. Again, this huge heterogeneity in guidelines is quite striking. And so when we assessed all the sites in the PRECEDE Consortium, we found some really interesting results with respect to these particular genes. For BRCA2 carriers specifically, we found that about half of the sites required a family history for recommending pancreatic cancer screening, but about half of the sites would offer it to all BRCA2 carriers regardless of if there was a family history of pancreatic cancer screening. Rates for BRCA1, PALB2, and ATM carriers were a little bit lower, where about a third of sites would offer screening really regardless of whether or not there is a family history of pancreatic cancer. And for Lynch syndrome, those rates were very, very low, with only about 13% of sites offering screening to Lynch patients in the absence of a family history. But I think, you know, we are all in the same consortium, but there is still just a lot of heterogeneity in how our own individual practices are run. Dr. Rafeh Naqash: Definitely different thoughts, different practices. But from what you saw, did it matter as far as outcomes are concerned whether it was a gastroenterologist doing the screening, or it was a medical oncologist, or a geneticist? Or is it a combination of all of these that actually makes the most difference? Dr. Bryson Katona: So I think we do need to get some more information about specialty-specific screening preferences. We just had one response per site in this particular survey, and so I think we are going to need a larger sample size in order to get that data. But I think that is certainly possible that, you know, certain subspecialties may prefer, you know, screening more aggressively or not including family history. That is definitely a question that we will be asking in future studies. Dr. Rafeh Naqash: Definitely more gift cards that will be needed as well. Moving on to another aspect of the implications for early detection, from a breast cancer, colon cancer standpoint, there is health economics research that shows it saves cost in the bigger picture. Has there been anything for pancreas cancer where early detection, early identification, early treatment actually ends up saving a lot more versus detecting metastatic pancreas cancer later? Dr. Bryson Katona: It is a great question. And of course, for any screening modality, you know, we would ultimately want it to be a cost-effective measure. In pancreas cancer screening, the jury is still a little bit out about whether or not pancreas cancer screening is truly cost-effective or not. There have been several different studies that have assessed this. And I think in general, the thought is that it is a cost-effective endeavor. But I think most of these cost-effectiveness estimates are actually related to what is the risk of pancreatic cancer in the population you are studying. And so when you have very, very high-risk individuals that have over a 10% lifetime risk of pancreatic cancer, it is almost a certainty that pancreatic cancer screening is going to be cost-effective. However, you know, if you have, say for example, BRCA1 carriers where lifetime risk of pancreatic cancer may be less than 5%, likely around like 3%, those individuals, I think it is going to be a tougher sell to say that it is cost-effective. But as we get more data on pancreatic cancer screening, that will be a very important question to ask. And you know, when you mentioned how does it save money, our goal at least in pancreatic cancer screening is to really downstage pancreatic cancer at the time of diagnosis and allow someone to undergo, you know, ideally a curative-intent surgery. There is data out there showing that we can downstage the cancers, that survival after the time of diagnosis is substantially increased after detection in a pancreatic cancer screening program. But again, these are studies that are based on fairly small numbers of converters. And so I think we need more data in that space as well, which is one of the main questions that the PRECEDE Consortium is trying to answer with all of our prospective data. Dr. Rafeh Naqash: Excellent. Well, I hope we see more interesting, exciting work from the PRECEDE Consortium at meetings as well as as a publication in JCO PO. I would like to shift gears briefly for a minute or two, Bryson, to you as an individual, your career. How have you evolved over the last 5, 7 years? How did you end up doing cancer genetics? What were some of the lessons that you learned along the way and some of those that you would want to share with our listeners, especially trainees and early-career faculty? Dr. Bryson Katona: Just to give you and others listening a little bit of background, but I am a physician-scientist, gastroenterologist, but a physician-scientist. And so my clinical practice is exclusively focused on individuals with hereditary GI cancer risk. I run a basic science lab where we do a lot of studies in organoids and mouse models of these hereditary GI cancer risk syndromes. And then I also have a clinical research group where we do early-phase clinical trials and screening and early detection trials, again in these same individuals with hereditary GI cancer risk. I think probably the most important thing that kind of allowed me to get to this stage in my career where I am trying to, you know, essentially try to juggle all three of these balls at the same time is that I absolutely love what I do. And I am so incredibly interested in what I do. And I think for young individuals that are coming through the pipeline and going through training, you know, I mean, finding a specialty and a clinical niche where you truly just enjoy the work and you enjoy the patients and you enjoy your colleagues is by far the most important thing. I ended up getting into the hereditary GI cancer space because a lot of my work earlier on in my career during my PhD and then in my postdoc work in the lab really focused on colorectal cancer. And I thought that focusing on cancer genetics could allow me to really continue to think from the molecular side of things while simultaneously being a gastroenterologist and taking care of patients with hereditary cancer risk. Dr. Rafeh Naqash: Well, thank you so much for giving us a sneak peek of your journey and insights on what perhaps works best, especially when you love what you do. I think that is one of the most important reasons a work tries to keep you going and keep you interested, keep you passionate. So thank you again. Thank you for listening to JCO Precision Oncology Conversations. Do not forget to give us a rating or a review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

In this episode of the Tough Girl Podcast, I'm joined by the incredible Julie Weiss — also known as The Marathon Goddess. Julie's story is one of resilience, healing, and purpose. After losing her father to pancreatic cancer, she set out on an extraordinary mission: to run 52 marathons in 52 weeks, raising awareness and funds for pancreatic cancer research along the way. Her journey captured hearts around the world — from the Today Show and O Magazine to countless finish lines across the US. But behind the medals and media attention is a woman who found strength, joy, and hope through running. Now in her fifties, Julie has completed over 118 marathons, raised more than $1 million for research, and continues to inspire others with her message that it's never too late to chase your dreams, honour your loved ones, and find purpose in every step. In this conversation, Julie opens up about:  How running helped her heal from grief and depression  The challenges and triumphs of running 52 marathons in 52 weeks  What it takes to stay motivated and injury-free through massive goals  Her empowering “7 C's to Defy Your Limits” — Create, Certainty, Connect, Commit, Consistent, Cause, and Courage Julie's story is a beautiful reminder that transformation begins with one small step — and that every mile can make a difference.  New episodes of the Tough Girl Podcast drop every Tuesday at 7 AM (UK time)! Make sure to subscribe so you never miss the inspiring journeys and incredible stories of tough women pushing boundaries.  Do you want to support the Tough Girl Mission to increase the amount of female role models in the media in the world of adventure and physical challenges? Support via Patreon! Join me in making a difference by signing up here: www.patreon.com/toughgirlpodcast.  Your support makes a difference.  Thank you x Show notes Who is Julie Living in Santa Monica,  California, USA Being known as the Marathon Goddess - Running 52 marathon in 52 weeks Raising over $1 million for charity  Being excited to share the wisdom she has leaned from running marathons Her childhood and early years  Being tall with long legs Starting running at 37 years Not being at athlete at school Taking a different path Becoming a mother at 18  Not doing a lot of exercise in her younger years  Feeling at a very low point in her life Going for that first run on the beach  Wanting to feel good Keeping on running  Coming off anti-depressants  Fitting running into her life and making it work for her Joining a running group LA Road Runners Connecting with other people  Training for a triathlon first  Running her first marathon in March 2008 How running makes her feel  Her relationship with her dad Raising funds for Hirshberg Foundation for Pancreatic Cancer Research Taking 10 years to raise the funds  Project Purple Deciding to run 52 marathons in 52 weeks The Marathon Guy Being determined  Feeling overwhelmed at the start of the goal The start and the different steps involved Reaching out to charities, speaking to her boss The power of having purpose  The physicality of the challenge Protein, stretching, foam rolling, strength training, rest, compression tights, physio  The standout marathons from the challenge  The Leadville Marathon and the challenges of running at altitude   The Lake Tahoe Marathon The New York Marathon in 2012 - being cancelled   Marathon proposal! Being coached by her husband Qualifying for the Boston Marathon Losing her dad 19th attempt of getting into Boston Marathon Making the decision to run 52 marathons in 52 weeks Not giving up  The mental side of the challenge The importance of creating a goal that is important to you The 7Cs - Create, Certainty, Connect, Commit, Consistent, Cause, Courage  Enjoying what you've accomplished Writing her book  BOOK: The Miles and Trials of a Marathon Goddess: 52 Weeks, 52 Marathons Advice for deciding what to do? The importance of fun Chasing speed and wanting to quality for Boston again Running during peri-menopause and menopause Struggling with the lack of sleep and dealing with a lack of iron Compassion Reaching her 100th Marathon at the LA Marathon  Needing to keep on going  Being supported by her friends The importance of enjoying the journey and finding the joy How to connect with Julie  Words by ― CS Lewis “You are never too old to set a new goal or to dream a new dream.”   Social Media Website: www.julie-weiss.com  Instagram: @marathongoddess  Facebook: @Julie-WeissMarathonGoddess  

What is the real reason 90% of businesses fail? What are some bookkeeping or CFO mistakes most business owners make that can tank your business? On this week's episode of The Crushing Debt Podcast, George and Shawn talk to Emily Handren, owner and founder of Besty Bookkeepers (www.BestyBookkeepers.com).  For over two decades, Emily has helped individuals and businesses improve their financial situations through banking, investing, lending, and insurance guidance. She has owned both life/health and P&C agencies, and has plenty of real-world stories about helping people reduce costs and increase their net worth. Emily recently wrote a book "The Real Reason 90% of Businesses Fail: 101 Bookkeeping and CFO Mistakes You Can't Afford to Make"  that hit #1 in three categories: Small Business Bookkeeping, Entrepreneurship Management, and Business Planning & Forecasting. It focuses on practical money management strategies for businesses that could tie perfectly into debt reduction discussions. Here's the link if you'd like to check it out: https://a.co/d/2JDV3So In this episode, we talk about: Fractional CFO Bookkeepers v. Accountants Tech stacking Financial Forecasting Some of the 101 Mistakes, like: Exponential growth without a plan or foundation Improperty business structure knowing your expenses and your numbers using an outdated accounting system not paying yourself. You can reach Emily at her website www.BestyBookkeepers.com or Emily@BestyBookkeepers.com. Make sure you take the "Need a Better Bookkeeper" quiz on her website! Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026 

Synthetic progestogens hike risk for brain tumors, natural progesterone safe; Healthy microbiome, good genes, clean lifestyle propel world's oldest woman to age 117; Can you take too much selenium? Cannabis extract scores vs. low back pain; Can vitamin K prevent breast calcifications? Are we making progress vs. pancreatic cancer? 

Vidcast:  https://www.instagram.com/p/DPa20mdDoub/University of Cincinnati oncologists have developed a drug that stops pancreatic cancer from suppressing the anti-tumor immunity that threatens to eradicate it.  Using a pre-clinical mouse pancreatic cancer model, the researchers pinpointed that the protein Hsp70 is produced by the cancer cells to defuse the anti-cancer immune response.Their next step was to find an antidote Hp70.  That they did by developing the rescue agent SapC-DOPG.  This drug adheres to pancreatic cancer cells, inhibits Hsp70, and destroys the tumor's shield against killer T lymphocytes.The next step is to bring this rescue compound and others like it into the clinic for an array of trials.  Hopefully, they will confirm the effectiveness of this concept and join the fight against this dread disease…..someday soon.#pancreatic #cancer #immunotherapy #hsp70 #sapCDOPGpancreatic, cancer, immunotherapy, hsp70, sapCDOP

What is the test for discharging a student loan in bankruptcy? Is it even possible? Student loans are non-dischargeable, right? WRONG !! On this week's episode, Shawn is back solo again (we'll hear George back again for next week's episode) interviewing attorney Jeff Hakanson.  Jeff has been an attorney for thirty (30) years! He granduating with his J.D. from South Texas College of Law and has practiced bankruptcy for his entire career.  On November 17, 2022, the U.S. Department of Justice issued a memorandum on student loan discharges.  What normally fell under the Brunner case and a Totality of Circumstances argument has now been streamlined by the US DOJ to assist in discharging student loan debts under certain circumstances, some of which include: The borrower is over 65; The borrower has a disability; The borrower has been unemployed 5 of the last 10 years; The borrower has attempted repayment in good faith. Typically these discharge cases are started with the filing of an Adversary Proceeding (with no fee if related to Student Loans) and then the debtor / borrower and attorney complete a "litigation package" with certain "attestations."  If the DOJ agrees, then the student loans can be discharged, or maybe modified in some capacity. The memorandum was designed to allow borrowers more clarity on discharging federally backed student loans (not private loans). Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com.   And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team (reactivated for 2026) at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026   

Pancreatic cancer is among the deadliest forms of cancer, and Pennsylvania has one of the nation’s highest rates. For families like the Crosbys of Cumberland County, the disease has left a lasting mark — one they hope can spark more awareness, early detection, and support. The beginning of the school year is an exciting time, but many children will fall behind academically, developmentally and socially because of undetected vision issues. That is the concern of the Pennsylvania Optometric Association, POA, and the reason state lawmakers are sponsoring the Children’s Vision Bill. It calls for optometrists and ophthalmologists to perform vision exams at milestone years for students: kindergarten, fourth and eighth grades. The National Parent Teacher Association has reported that more than 10 million children in the U.S. suffer from undetected vision problems that can hamper learning success. Identifying those students who have vision-related deficiencies early on and getting them an effective diagnosis and treatment will make a significant impact on their overall quality of life and future. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world.## Immuneering's drug atebimetinib has shown promising results in doubling overall survival in pancreatic cancer patients after nine months. Truist analysts have deemed the results encouraging, although some unknowns remain in the data. Immuneering plans to initiate a registrational trial for atebimetinib later this year. ## In other news, Lilly has halted a mid-stage obesity study for strategic reasons, Harmony has failed a pivotal trial for fragile X syndrome, and the FDA has released guidance to streamline the development of cell and gene therapies. Overall, Immuneering's drug shows potential in improving survival rates for pancreatic cancer patients, with further trials planned for the future.

In this extremely motivational episode of the Project Purple Podcast, host Dino Verrelli speaks with Michael Kennedy of Vermont, a lawyer and avid runner whose 20 years on the roads and trails unexpectedly prepared him for the toughest marathon of his life: pancreatic cancer. Michael shares how his story began in 2023, a year packed with long runs, two marathons, and a 100‑mile relay. But when back pain crept in after the relay, he brushed it off as age or overtraining. But within weeks, his symptoms escalated: rapid weight loss, changes in digestion, and eventually, a scan soon confirmed what no runner expects to hear: a tumor was on his pancreas. He recounts how his diagnosis in October 2023 launched him into treatment with the same discipline he'd honed as an athlete. Michael reflects on the months of chemotherapy, the neuropathy that forced him to wear mittens just to grab milk from the fridge, and the exhausting stretch of radiation—all to make surgery possible. In June 2024, he underwent a Whipple procedure with an innovative addition he advocated to have: a cutting‑edge CIVASheet radiation implant that allowed him to avoid post‑surgery chemo. Michael also describes how, even through treatment, he kept running. Running became a lifeline: “It's not gonna take the things from me unless it beats 'em out of me,” he says. He explains how discovering Project Purple gave him something to look forward to: a goal of finishing a marathon in the same calendar year as his Whipple surgery. Just months after leaving the hospital, he crossed the finish line of a December marathon in Jacksonville wearing a Project Purple singlet, and has since completed other races with the organization. In this conversation, Mike opens up about scanxiety, hope, and the power of staying positive. He discusses how his runner's mindset and experience being a high school basketball coach have taught him that you can do hard things one step at a time, which helped him through chemo and into recovery. And he offers practical advice: know the symptoms, and when life hands you a challenge, focus on WIN: What's Important Now. Mike's story is one of three Ps: positivity, perseverance, and the unexpected ways our passions can prepare us for life's biggest battles. You can find Mike on Instagram at: http://instagram.com/mkennedyvt/ Subscribe to the Project Purple Podcast to hear more stories from the pancreatic cancer community. And, if you'd like to learn more about or donate to Project Purple's mission of a world without pancreatic cancer, please visit https://www.projectpurple.org/.

Evening Prayer (people with pancreatic cancer)  #prayer #pray #eveningprayer #jesus #god #holyspirit #aimingforjesus #healing #bible #love #peace #pancreaticcancerThank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

Pancreatic cancer is among the deadliest forms of cancer, and Pennsylvania has one of the nation’s highest rates. For families like the Crosbys of Cumberland County, the disease has left a lasting mark — one they hope can spark more awareness, early detection, and support.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD. Related Content: Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer

Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD. Related Content: Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer

Immunotherapy is not usually effective against pancreatic cancer (PC), but a new study published in Oncotarget (Volume 16, 2025) highlights rare cases where it did help. These examples, though uncommon, may offer valuable insights for future treatment. Pancreatic Cancer and Immunotherapy Pancreatic cancer is often diagnosed at an advanced stage, which limits treatment options and contributes to its poor prognosis. While chemotherapy remains the standard treatment, it usually offers only modest benefits in terms of survival. Immunotherapy—an approach that activates the immune system to fight cancer—has been effective in other cancers but has shown limited success in PC. This is largely due to the tumor's ability to suppress immune responses and create an environment that protects it from attack. Currently, these drugs are only approved for a small subset of patients whose tumors have a specific genetic feature called high microsatellite instability (MSI-high), found in just 1 to 2 percent of cases. The Study: Pancreatic Cancer Immunotherapy Responders The study, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence,” was led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center. The researchers examined medical records from 14 patients with pancreatic ductal adenocarcinoma (PDAC) who had responded unexpectedly well to immune checkpoint inhibitors—drugs that help reactivate immune cells to attack cancer. The drugs included PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting tumor-associated macrophages. To find these rare cases, the research team contacted 471 oncologists from 91 major U.S. cancer centers between 2020 and 2021. Full blog - https://www.oncotarget.org/2025/09/11/immunotherapy-response-in-pancreatic-cancer-what-a-new-study-reveals/ Paper DOI - https://doi.org/10.18632/oncotarget.28739 Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org Abstract video - https://www.youtube.com/watch?v=VeWTcuVmqgM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, pancreatic adenocarcinoma, immunotherapy, exceptional responders, microsatellite instability, survival To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode of the Project Purple Podcast, host Dino Verrelli speaks with Carmen Stewart, a pancreatic cancer survivor from across the globe, calling in all the way from Johannesburg, South Africa. Her story is one of perseverance, clarity, and transformation in the face of staggering odds. Carmen opens up about her whirlwind diagnosis in 2020 at the height of the pandemic, which followed months of persistent pain, varying symptoms, and repeated misdiagnoses, from gastroenteritis and hepatitis. She talks about how she pushed for surgery before lockdown hit in her country, against her doctor's initial plan, and how she underwent a Whipple procedure alone, with no support system allowed into the hospital due to pandemic restrictions. She goes into detail about her surgery, saying her surgeon called it a “miracle,” as her tumor had been capped and fully contained, preventing the cancer from spreading. Carmen explains her recovery wasn't easy—it was complicated by sepsis, delays in chemotherapy, a contraction of COVID-19, and the emotional toll of isolation. Still, she forged ahead, adding that it was the help of natural therapies, the love of and from her daughters, and an unwavering will to survive that kept her going. Carmen speaks candidly about survivor's guilt and the reality of life after treatment, which changed drastically for her in many ways. Her perspective is grounded in realism: “If it comes back, I'll deal with it. But if I'm clear, that's great.” She discusses how her experience reshaped her life—from managing her health and finishing her degree, to letting go of fear and finding joy in the present. Her message is clear: trust your instincts, choose the right medical team, and don't ignore what your body is telling you. Tune in to hear Carmen's candid conversation about navigating illness during a global crisis, rebuilding after the trauma that comes with this disease, and finding meaning in survival. Subscribe to the Project Purple Podcast to hear more stories from the pancreatic cancer community. To learn more or donate to Project Purple's mission of a world without pancreatic cancer, please visit https://www.projectpurple.org/.

Honoring Lori: fighting pancreatic cancer with purpose Jennifer Peterson and Nicole Hawes are on the board of the Lori Peterson Cancer Foundation, which was created to honor the life and legacy of Lori Lynn Peterson, who courageously battled pancreatic cancer. Carrying forward her spirit, the organization is dedicated to advancing research, supporting treatment, and raising awareness for one of the toughest cancers to fight. The foundation has funded projects that bring hope, progress, and real impact for patients and families. They are turning loss into legacy and making a difference in the fight against pancreatic cancer.  

Potato intake and diabetes risk.How much daily leucine is required to regain muscle?

I have high LDL cholesterol and a '0' calcium score.  Why does my doctor insist I take a statin?How much vitamin D should I take?  Which product do you recommend?Some doctors assert omega-3s are proinflammatory.  What say you?Study: Magnesium intake may be beneficial in preventing pancreatic cancerDo you have any products to regrow hair?I have a calcium score, but prefer to avoid Lipitor.

In today's episode, we passed the mic to Tara E. Seery, MD, who moderated an OncLive Insights discussion on the future of the pancreatic cancer treatment paradigm. Rounding out the discussion with additional expert perspectives were Paul E. Oberstein, MD, and Priyadarshini Pathak, MBBS. Seery is a medical oncologist at the Hoag Family Cancer Institute in Newport Beach, California. Oberstein is an associate professor in the Department of Medicine at the New York University (NYU) Grossman School of Medicine; as well as the director of the Gastrointestinal Medical Oncology Program, the assistant director of the Pancreatic Cancer Center, and the service chief of the Gastrointestinal Medical Oncology Program at NYU Langone's Perlmutter Cancer Center. Pathak is an assistant in medicine at Massachusetts General Hospital and an instructor in medicine at Harvard Medical School in Boston.  In this exclusive conversation, Drs Seery, Oberstein, and Pathak highlighted key data from the phase 3 NAPOLI 3 trial (NCT04083235) of NALIRIFOX (liposomal irinotecan, 5-fluorouracil [5-FU], leucovorin, and oxaliplatin) vs nab-paclitaxel (Abraxane) and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma; the toxicity profiles of NALIRIFOX and FOLFIRINOX (leucovorin, 5-FU, irinotecan, and oxaliplatin); real-world data with these regimens, and more. 

Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O'Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including:How patients often present with disease-related symptomsTreatment selection considerations for the first-line and second-line settingHow to approach palliative care discussions with patientsEmerging therapies that are showing promise in this settingPresentersPaul E. Oberstein, MDAssociate Professor of MedicineSection Chief, GI OncologyPerlmutter Cancer CenterNYU Langone HealthNew York, New YorkMark O'Hara, MDAssociate Professor of MedicineDivision of Hematology and OncologyUniversity of PennsylvaniaPhiladelphia, PennsylvaniaZev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaLink to full program: https://bit.ly/45NdBTx

Maria Fundora, Purple Pansies: Fighting Pancreatic Cancer (North Fulton Business Radio, Episode 898) Maria Fundora, founder of Purple Pansies and owner of Casa Nuova Italian Restaurant, joined host John Ray on North Fulton Business Radio to share her mission to fight pancreatic cancer. After losing her mother to the disease, Maria turned personal loss into […] The post Maria Fundora, Purple Pansies: Fighting Pancreatic Cancer appeared first on Business RadioX ®.

Maria Fundora, Purple Pansies: Fighting Pancreatic Cancer (North Fulton Business Radio, Episode 898) Maria Fundora, founder of Purple Pansies and owner of Casa Nuova Italian Restaurant, joined host John Ray on North Fulton Business Radio to share her mission to fight pancreatic cancer. After losing her mother to the disease, Maria turned personal loss into […]

Tamar Braxton wakes up in a pool of blood, missing memories, broken teeth, and a fractured nose. What on earth happened? We're getting right into the heart of this headline. Let's break down the real possibilities together: sudden health crisis or something more sinister?We'll also talk about Judge Frank Caprio, the “nicest judge in the world,” and his fight with pancreatic cancer. There are lessons here for all of us about warning signs and risks.Jason Momoa's surfing accident made him quit smoking overnight - not for his kids or his ex, but because he was face-to-face with danger. Let's talk about the moments that make people finally change their bad habits.Did you hear that Serena Williams shared the real reason for her recent weight loss? Let's talk about it! And don't miss our discussion on comedian Guy Torry's blood clot scare - would you know what to do? We'll explain what a pulmonary embolism is and the symptoms you can't afford to ignore.This podcast is intended to be informational only.  It is not a medical consultation, nor is it personalized medical advice.  For medical advice, please consult your physician.#HealthHappyLifePodcast #DrFrita #MedicalMondays #CelebrityHealthNews #MedicineInTheNewsHere are a few helpful resources to help on your journey to wellness:▶️ Subscribe so you will never miss a YouTube video.

Vidcast:  https://www.instagram.com/p/DN0-HNvXPcP/An already FDA-approved cancer vaccine was spectacularly effective in controlling pancreatic cancers that carry the KRAS markers.  A multi-center phase 1 study, helmed by oncologists at New York's Sloan Kettering and Texas' MD Anderson, studied the vaccine labeled ELI-002 developed by Boston's Elicio Therapeutics.  The results demonstrated that the vaccine can trigger a vigorous killer T cell response to this KRAS marker carried by 88% of pancreatic cancers. They also showed that 65% of patients who mounted this T cell response to the vaccine enjoyed no radiographic progression of their cancers.  Even more exciting, five of the sewpatients were free of tumor relapse without any subsequent therapy following the vaccine.  When the study ended after nearly 20 months, these excellent responders were all alive without evidence of cancer recurrence.  In contrast, the untreated controls developed cancer relapses in an average of 3 months and only survived an average of 15 months.Unlike most cancer vaccines that are custom produced for each patient's tumor, ELI-002 can be mass produced making it readily available for administration and less expensive.  A phase 2 trial of the vaccine is already in progress.Pancreatic cancer is one of the deadliest cancers, with only about 13% of patients surviving five years after diagnosis and recurrence rates as high as 80% within two years of surgery. Hopefully, this vaccine immunotherapy will help change those dismal statistics.https://www.nature.com/articles/s41591-025-03876-4#cancer #pancreatic #vaccine #ELI002 #elicio #iommunotherapy

This month, the Department of Health and Human Services terminated almost $500 million in mRNA vaccine development grants and contracts. While HHS has said that these cuts won't affect mRNA cancer research, some researchers have expressed concern about the impact on their ongoing work. In light of these developments, we're revisiting a conversation from February.A team at Memorial Sloan Kettering is developing an mRNA vaccine for pancreatic cancer, which is notoriously difficult to treat. A few years ago, the team embarked on a small trial to test the vaccine's safety. Sixteen patients with pancreatic cancer received it, and half of them had a strong immune response. A follow-up study found that in six of those patients, the cancer hadn't relapsed after three years.Host Flora Lichtman spoke to study author Vinod Balachandran about the work, which has not yet been affected by the cuts, according to Memorial Sloan Kettering.Guest: Dr. Vinod Balachandran is an associate attending surgeon and Director of The Olayan Center for Cancer Vaccines at Memorial Sloan Kettering in New York, New York.Transcripts for each segment will be available after the show airs on sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Dr Bill Nelson and Dr Michael Pishvaian discuss the targeting of KRAS mutations in pancreatic cancer to develop new treatment options for a disease that has been historically difficult to care for.

Bill Perkins, founder of Top Fan Rivalry, a baseball-centered community organization and a pancreatic cancer survivor, speaks with host Dino Verrelli in this powerful episode of the Project Purple Podcast. Hailing from Laguna Beach in the OC, Bill's story is as candid as it is inspiring. He shares how a moment in early 2022, when his wife noticed he looked jaundiced, set off a whirlwind of tests that led to a shocking diagnosis. What doctors first believed was a harmless blockage turned out to be pancreatic cancer. Within weeks, Bill underwent a grueling Whipple procedure, followed by a slow recovery and seven months of intense chemotherapy. He describes the emotional toll of being just 46 years old and hearing words like “life expectancy,” the terrifying stretch when a misread scan made it seem like the cancer had returned, and the strength it took to face survivor's guilt even after being declared cancer-free. Through it all, Bill credits faith, humor, a mental commitment to never giving up, and his wife's unwavering support as his anchors. A lifelong baseball fan, he opens up about how MLB's Stand Up To Cancer tribute moves him to tears and why a Rocky quote—“It ain't about how hard you hit, it's about how hard you can get hit and keep moving forward”—became his mantra. Now, more than three years out from surgery, Bill is channeling his resilience into helping others. Partnering with Project Purple, he's walking the equivalent distance from Dodger Stadium to Yankee Stadium (2,791 miles!) to raise awareness and prove that “you can do hard things,” hoping his journey inspires anyone facing dark days. Bill's advice is simple but hard-earned: be patient, fight with your loved ones by your side, keep a positive attitude, and remember, “the sun always comes up the next day.” Tune in for an episode full of honesty, perspective, and hope as Bill reminds us what it means to get knocked down, get back up, and keep moving forward. To support Bill's fundraising efforts, visit https://donate.projectpurple.org/campaign/694042/donate. Subscribe to the Project Purple Podcast for more stories from the pancreatic cancer community. If you'd like to donate to Project Purple's mission of a world without pancreatic cancer, please visit www.projectpurple.org/.

In episode 92 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Joyce Irwin, President/CEO of the Community Health Network Foundation. Tune in as Joyce shares the genetic testing that led to her double mastectomy, her pancreatic cancer diagnosis, and how she's giving back through her work at the Community Health Network Foundation.

You might remember Alicia Purdy's first interview quite a while ago...now she's back with some more incredible nudges from God.  She thought she was going this way; God said, "Nope!  You're going THAT way!"Scripture mentioned:Isaiah 51Ps 40:1-3Neh 8:10Ps 22:3Ps 16:11Isaiah 55:11Reach Out to Me:Website: www.dontignorethenudge.comPatreon: www.patreon.com/dontignorethenudgeIG: @dontignorethenudgepodcastPrivate FB group to WATCH interviews: www.dontignorethenudge.com/facebook__________________________________________________________________________________________Business/Personal Coaching with Cori:www.corifreeman.com(951) 923-2674Reach Out to Alicia Purdy:Book and Devotional Link: The Way of the Worshipper: https://thewayoftheworshipper.com/ (the books can be purchased here, and the devotional, journalism-style blog articles are all here as well) YouTube: Read the Bible in a Year: https://www.youtube.com/@thewayoftheworshipperMy brother's mission, "Heroes & Horses" https://heroesandhorses.org/Link to purchase "THEY" on hard copy or Kindle: https://www.amazon.com/THEY-Alicia-Purdy/dp/B0CR813N57?

In this new episode of Speaking of SurgOnc, Dr. Rick Greene discusses with Dr. David Seo recent and ongoing high-impact clinical trials that analyze the multidisciplinary treatment of pancreatic ductal adenocarcinoma, as reported in the article, "The Landmark Series: The Future of Pancreatic Cancer Clinical Trials.”

You might remember Alicia Purdy's first interview quite a while ago...now she's back with some more incredible nudges from God.  She thought she was going this way; God said, "Nope!  You're going THAT way!"Scripture mentioned:Isaiah 51Ps 40:1-3Neh 8:10Ps 22:3Ps 16:11Isaiah 55:11Reach Out to Me:Website: www.dontignorethenudge.comPatreon: www.patreon.com/dontignorethenudgeIG: @dontignorethenudgepodcastPrivate FB group to WATCH interviews: www.dontignorethenudge.com/facebook__________________________________________________________________________________________Business/Personal Coaching with Cori:www.corifreeman.com(951) 923-2674Reach Out to Alicia Purdy:Book and Devotional Link: The Way of the Worshipper: https://thewayoftheworshipper.com/ (the books can be purchased here, and the devotional, journalism-style blog articles are all here as well) YouTube: Read the Bible in a Year: https://www.youtube.com/@thewayoftheworshipperMy brother's mission, "Heroes & Horses" https://heroesandhorses.org/Link to purchase "THEY" on hard copy or Kindle: https://www.amazon.com/THEY-Alicia-Purdy/dp/B0CR813N57?

Nutritionist Leyla Muedin reveals the alarming increase in obesity-associated cancers in the United States over the past two decades. Highlighting findings from a recent study presented at the Endocrine Society's annual meeting, Leyla underscores the significant rise in cancer deaths linked to obesity, particularly among women, older adults, Native Americans, and Black Americans. She also explores the complex causes of obesity, including genetics, lifestyle, and environmental factors, and offers insights into effective weight management strategies. Additionally, Leyla examines the high rates of heart disease in various U.S. states, emphasizing the importance of lifestyle modifications and public health initiatives to combat cardiovascular diseases.

Dr. Joshua Kays, is a board-certified surgeon with additional training in Complex General Surgical Oncology. He specializes in the surgical treatment of liver, pancreas and bile duct disease.

In this episode of the Project Purple Podcast, host Dino Verrelli speaks with Lew Worthington, a former pastor and seminary professor turned author from Lansing, Michigan. He courageously shares his remarkable journey with Stage 4 pancreatic cancer, describing how a persistent side pain quickly turned into a life-altering diagnosis in 2020 that he was told gave him just months to live. Lew recounts to listeners the difficult road he had ahead of him, undergoing intensive chemotherapy, targeted radiation, and devastating side effects. He mentions that, despite the odds of survival, he reached remission, only to face a recurrence of cancer that tested his resolve and faith once again. Fortunately, Lew shares that his health is stable, and he stays active playing tennis two to three times a week. Despite the bleak statistics surrounding pancreatic cancer, Lew's resilience propelled him forward. His story goes far beyond the medical, exploring profound reflections on life, hope, mortality, and spirituality. He grapples with the “why” of suffering and shares how his faith evolved through moments of doubt and acceptance. Lew also talks about the importance of compassion, not just from loved ones, but from the wider community. He discusses his recent book, Unlikely Hope: My Journey From Dying to Living with Pancreatic Cancer, a thoughtful autobiography that chronicles not only his two-time battle with cancer, but also the meaning he discovered along the way, blending medical realities with philosophical and theological insights. Listen in on this moving conversation that offers not only a story of survival, but also encouragement to listeners to always cling to whatever hope they can find, all while advocating for improved early pancreatic cancer detection. Subscribe to the Project Purple Podcast to hear more stories from the pancreatic cancer community. Learn more about Lew on his website https://lewworthington.com/ and find his book on Amazon here https://www.amazon.com/Unlikely-Hope-Journey-Living-Pancreatic/dp/B0F896HY38. If you'd like to donate to Project Purple's mission of a world without pancreatic cancer, please visit www.projectpurple.org/. To learn more about Project Purple, visit www.projectpurple.org/ or follow us on social media at these links: www.facebook.com/Run4ProjectPurple www.instagram.com/projectpurple/ twitter.com/Run4Purple www.youtube.com/channel/UCgA8nVhUY6_MLj5z3rnDQZQ

BUFFALO, NY – July 24, 2025 – A new #casereport was #published in Volume 16 of Oncotarget on July 23, 2025, titled “Extracorporeal blood filtration leading to tumor growth arrest and reduced analgesic requirements in Stage IV poorly differentiated pancreatic adenocarcinoma: A case report.” In this report, Susanna Ulahannan from the University of Oklahoma Health Sciences Center and colleagues describe the use of extracorporeal blood filtration in a patient with metastatic pancreatic cancer. The patient experienced clinical improvement, reduced pain, and no signs of new tumor growth over 12 months of follow-up. Metastatic pancreatic cancer is difficult to treat and is often diagnosed at an advanced stage. In this case, a 51-year-old woman with stage IV poorly differentiated adenocarcinoma chose not to undergo standard chemotherapy. Instead, she received extracorporeal blood filtration with the Seraph® 100 device, which is designed to remove circulating tumor cells (CTCs) from the bloodstream. CTCs are thought to contribute to the spread of cancer to other organs. “Circulating tumor cells (CTC's) are tumor cells that are shed from the primary tumor and travel via blood or lymphatic system to form micro metastases in distant organs under a suitable environment.“ The patient received between nine and twelve treatments over the course of a year. These treatments were performed both abroad, where the device is approved for this use, and under a clinical protocol in the United States. Medical imaging showed that her disease remained stable, with no new metastases detected. She also reported improvements in appetite, energy levels, and pain control. Her opioid use was reduced by 90%. Blood samples confirmed a drop in CTC levels after treatment. This observation supports the idea that removing CTCs might help limit cancer progression in some patients. However, given that this is a single case report, larger clinical studies are needed to evaluate the effectiveness of this approach. The mechanism behind the patient's pain relief is not fully understood. Authors suggest that it may be related to the reduction of tumor cells or inflammatory molecules in the blood. Researchers noted that pro-inflammatory cytokines, known to influence pain, could also have been affected by the filtration process. This is the first documented case of stable disease and reduced symptoms following CTC filtration in advanced pancreatic cancer. While these findings should not be generalized, they highlight an approach outside standard protocols that should be further explored in clinical research. Future studies will be needed to determine whether this method can contribute to symptom management or disease control in other patients with metastatic pancreatic cancer. DOI - https://doi.org/10.18632/oncotarget.28756 Correspondence to - Susanna Ulahannan - susanna-ulahannan@ouhsc.edu Video short - https://www.youtube.com/watch?v=dro6iUGDrVQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28756 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, extracorporeal blood filtration, circulating tumor cells, metastatic pancreatic cancer, seraph 100, OncoBind To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Metastatic pancreatic cancer remains one of the deadliest cancers, but a new approach is taking shape - and it's showing promise in early clinical studies. In this episode, Dan Schmitt, President and CEO of Actuate Therapeutics, shares how elraglusib, an investigational targeted therapy, may provide a new option for patients with metastatic pancreatic cancer. We explore the urgent unmet need and why Dan thinks this could be a turning point for one of oncology's toughest challenges.

“I think that's what I would define pancreatic cancer as: never, ever give up.” In this powerful episode of the Project Purple Podcast, host Dino Verrelli speaks with Kelianne O'Shea, a 29-year-old from Cape May, New Jersey, who was diagnosed with stage four pancreatic cancer just one year ago. Now on maintenance chemo and marking a full year of what she calls “surviving pancreatic cancer,” Kelianne opens up about the physical and emotional rollercoaster of facing a devastating diagnosis at just 28 years old. She shares the story of her sudden symptoms and the ER visit that changed her life. Doctors initially gave her just months to live. But after a year of aggressive chemotherapy, her tumor has shrunk in half, and her medical team is hopeful. Kelianne reflects on how she navigated major life milestones, including getting married and going on her honeymoon, while undergoing treatment. Her story is one of strength, acceptance, and emotional honesty. She speaks candidly about the harm of toxic positivity, emphasizing the importance of allowing cancer patients to feel and express their emotions freely. “You don't always have to be positive,” she says. “Sometimes, you just want to be sad, and that's okay.” Now, Kelianne is sharing her journey publicly, using social media to educate others and connect with fellow survivors. From finding a cancer therapist to building a strong support system, her insights are heartfelt and grounded in experience. “This journey isn't linear,” she reminds listeners. Kelianne's story is a testament to perseverance and the healing power of connection. You can find her on Instagram https://www.instagram.com/keliannefield9/. Subscribe to the Project Purple Podcast for more powerful stories from the pancreatic cancer community. If you'd like to donate to Project Purple's mission of a world without pancreatic cancer, please visit https://www.projectpurple.org/. To learn more about Project Purple, visit https://www.projectpurple.org/ or follow us on social media at these links: https://www.facebook.com/Run4ProjectPurple https://www.instagram.com/projectpurple/ https://twitter.com/Run4Purple https://www.youtube.com/channel/UCgA8nVhUY6_MLj5z3rnDQZQ

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANG865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2026.Treatment Planning Made CLEAR in Neuroendocrine Tumors & Pancreatic Cancer: Personalized Integration of Validated & Emerging Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Let's Win, an affiliate of the Lustgarten Foundation, and Neuroendocrine Cancer Awareness Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

Send us a textIn this episode of WTR Small-Cap x Healthcare Spotlight crossover episode, we are joined by Lisata Therapeutics' (NASDAQ: LSTA) CEO David Mazzo, PhD and Chief Medical Officer Kristen Buck, MD to talk about, Certepetide, the company's novel solid tumor targeting and penetration technology with tumor microenvironment modifying properties.  We also dive into the recently reported positive preliminary results from Lisata's lead program (Ascend), a Phase 2b study investigating Certepetide for metastatic pancreatic ductal adenocarcinoma (the most common and aggressive form of pancreatic cancer), Lisata's partnerships, and upcoming milestones.  

Joyce discusses the Texas floods, What was the issue? Mother nature or lack of early warning systems? She also talks about the heroes. Japanese scientist link pancreatic cancer survival decline to the COVID-19 vaccine in certain cases. Elon Musk says he wants to start a third political party in the US, The FBI claims there was never an Epstein list, and ICE agents are being assaulted and the media seems to supports it.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I'm a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. In this episode, Dr. Warrick Bishop, a cardiologist and CEO of the Healthy Heart Network, discusses various health topics aimed at improving heart health and overall well-being. He emphasizes the importance of salt reduction, highlighting that the World Health Organization recommends consuming less than one teaspoon of salt daily. Research indicates that potassium-based salt substitutes can significantly reduce stroke and death risks. The podcast also covers bone health, clarifying that vitamin E may not be beneficial for bone density, while vitamins D and K2 are suggested for better bone and vascular health.